Longevity Biotech: The Billionaire Bet

The pursuit of extended lifespan, a desire echoing from ancient epics, is gaining traction with modern biotechnology. Leaders, including Russia's Putin and China's Xi, have discussed the potential for humans to live up to 150 years this century, spurred by advancements in regenerative medicine and organ transplantation.

Longevity biotechnology, a burgeoning field, aims to treat the biological mechanisms of ageing. This sector has seen a remarkable surge in investment, attracting billions and being hailed as the next major frontier after AI. Scientific breakthroughs in understanding the twelve hallmarks of ageing are driving this excitement.

The success of AI and highly effective obesity drugs has fostered a belief that complex biological challenges are now solvable. This optimism fuels significant investment in longevity companies, as a breakthrough in treating ageing represents a vast market.

However, significant hurdles remain. Ageing is a fundamental biological process, and manipulating it may lead to unforeseen side effects. Regulatory bodies like the FDA do not yet recognize ageing as a disease, requiring companies to prove benefits against specific conditions. Extensive clinical research will be necessary to ascertain the true potential and risks of these longevity therapies.